Click Banner For More Info See All Sponsors

So Long and Thanks for All the Fish!

This site is now closed permanently to new posts.
We recommend you use the new Townsy Cafe!

Click anywhere but the link to dismiss overlay!

Page 2 of 2 FirstFirst 1 2
Results 31 to 36 of 36

  • Share this thread on:
  • Follow: No Email   
  • Thread Tools
  1. TopTop #31
    Jon Jackson's Avatar
    Jon Jackson

    Re: Dr. Campbell's COVID-19 Update

    Dr. Campbell presents a COVID-19 update from Iraq. 08/28/20.

    | Login or Register (free) to reply publicly or privately   Email

  2. TopTop #32
    Jon Jackson's Avatar
    Jon Jackson

    Re: Dr. Campbell's COVID-19 Update

    Dr. Campbell's latest COVID-19 update. More on hydroxychloroquine (still not certain, but he is leaning toward LOW DOSE treatment being effective). And more on COVID re-infections (several cases now reported in the literature).

    The media is also reporting a re-infection case here in the United States.
    | Login or Register (free) to reply publicly or privately   Email

  3. Gratitude expressed by:

  4. TopTop #33
    Jon Jackson's Avatar
    Jon Jackson

    Re: Dr. Campbell's COVID-19 Update

    Here is Dr. Campbell's Global Weekend Update re: COVID-19. 08/29/20.

    I will be starting a new thread on WACCO starting September 1st for the September 2020 updates.
    | Login or Register (free) to reply publicly or privately   Email

  5. Gratitude expressed by:

  6. TopTop #34
    Jon Jackson's Avatar
    Jon Jackson

    Re: Dr. Campbell's COVID-19 Update

    Here is the last August COVID-19 update from Dr. Campbell.

    I will start a new thread tomorrow for the September updates.
    | Login or Register (free) to reply publicly or privately   Email

  7. Gratitude expressed by 2 members:

  8. TopTop #35
    Mayacaman's Avatar

    Re: Dr. Campbell's COVID-19 Update

    Quote Okay, folks. Get ready. Here is Dr. Campbell's update about hydroxychloroquine! 08/27/20.
    A study from Belgium suggests LOW DOSE hydroxychloroquine IS EFFECTIVE with COVID-19.
    Previous studies have been quite flawed...AND using way too high a dose.
    Dr. Campbell discusses these things in this video.
    COVID19 breaking news, August 28, 2020: New Belgian large-cohort
    study shows hydroxychloroquine significantly reduces mortality

    by Nitay Arbel

    Dr. John Campbell, a retired British nursing school instructor and textbook author whose videoblog on COVID19 I have been following diligently, highlights a new observational study from Belgium that caused him to change his mind about hydroxychloroquine: he was always skeptical but now believes it is effective.

    Hydroxychloroquine, evidence of efficacy

    The original paper “Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants” by L. Catteau et al., can be read here as a postprint (i.e., an accepted manuscript in press following peer review):

    Allow me to highlight some quotes from the actual paper:

    […]Early during the amplification phase of the epidemic in Belgium, and pending results of clinical trials, off-label administration of a low-dose regimen of HCQ sulphate in monotherapy (400mg twice on day 1, followed by 200mg twice a day from day 2 to 5, i.e. a total dose of 2400 mg) was recommended as an acceptable immediate treatment option for hospitalized COVID- 19 patients [8]. This guidance, officially released on March, 13th, was based on the following considerations: (1) HCQ was the only drug with demonstrated in vitro effect against SARS-CoV-2 available in Belgium at that time; (2) HCQ exhibited a superior in vitro antiviral effect in comparison to CQ, likely explained by the higher intracellular drug accumulated concentrations [9]; (3) limited pharmacokinetic data suggested that the selected dosage should have sufficient antiviral activity [10]; (4) chronic administration of HCQ for rheumatological disorders has not been associated with major safety signals since decades of use; (5) restricting HCQ use to well-selected COVID-19 patients monitored at hospitals appeared as a reasonable risk/benefit compromise considering the well-known dose-dependent cardiotoxicity of the drug; (6) it was advised to Belgian hospitals to administer this off-label regimen whenever possible within clinical studies.[…]

    Patients treated either with HCQ alone and supportive care (HCQ group) were compared to patients treated with supportive care only (no-HCQ group) using a competing risks proportional hazards regression with discharge alive as competing risk, adjusted for demographic and clinical features with robust standard errors. […] Results: Of 8075 patients with complete discharge data on 24th of May and diagnosed before the 1st of May, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively. In the multivariable analysis, the mortality was lower in the HCQ group compared to the no-HCQ group (adjusted hazard ratio [HR] 0.684, 95% confidence interval [CI] 0.617–0.758). Compared to the no-HCQ group, mortality in the HCQ group was reduced both in patients diagnosed ≤ 5 days (n=3975) and > 5 days (n=3487) after symptom onset (adjusted HR 0.701, 95% CI 0.617–0.796 and adjusted HR 0.647, 95% CI 0.525–0.797, respectively).

    The senior authors are affiliated with Ghent University, but the sample is nationwide, namely: all hospital admissions with COVID19 in Belgium until May 24 for which proper documentation on admission and discharge could be secured, and who had been given either HCQ or just “standard of care” (i.e., patients who got other experimental treatments were excluded, whether or not they also received HCQ).

    So what do the authors speculate about the mechanism?

    Antiviral efficacy of HCQ in humans has been poorly studied so far with adequate methods. Questions have also been raised whether safe HCQ dosages are sufficient to reach antiviral activity in target pulmonary cells [34]. Translating in vitro data into in vivo drug concentration in tissue appears particularly challenging for HCQ, as plasma concentrations do not appear to be a reliable surrogate [35]. Preprint studies in animal models (non-humans primates and Syrian hamsters) also suggest that HCQ has no antiviral efficacy [36,37]. Clinical efficacy might however be mediated through immunomodulatory mechanisms [7], preventing the progression toward severe disease with over-inflammatory responses by dampening the cytokine storm [38]. HCQ has indeed been shown to decrease the production of pro-inflammatory cytokines, both ex vivo and in lung explant model [5,39,40]. In the same line, use of low-dose dexamethasone (one of the RECOVERY arm) was recently reported to significantly decrease mortality in COVID-19 patients requiring oxygen [28]. Also, HCQ has been suggested to have some anticoagulant properties that may be beneficial in preventing thrombotic events in complement to low-molecular weight heparin [41].

    The authors also note that concerns about cardiotoxicity refer to much higher dosage regimes (12,000 mg over 10 days). I know anecdotally from a friend who got such high doses as standard treatment for acute malaria that this was not a pleasant experience. The low dosage regime considered here is normally associated with the management of autoimmune diseases like lupus and rheumatoid arthritis; anecdotally, friends and acquaintances have been taking such for years without serious adverse events. As Paracelsus so memorably wrote in 1538, “All things are poison and nothing is without poison; only the dose causes something not to be a poison” (Alle Dinge sind Gift, und nichts ist ohne Gift, allein die Dosis macht dass ein Ding kein Gift ist.)

    [ Source ]


    @ 8:00 in the video, Dr. Campbell asks a serious Question: essentially, 'Why did the previous studies administer such large dosages, when the "appropriate dose" in the British National Formualary has always been 200 mg ?'

    Dr. Campbell expresses his surprise at this flaw in the previous studies, but doesn't seem to grasp the obvious answer.

    To wit: All the previous studies on the efficacy of Hydroxychloroquine /& Zinc as an effective antidote for SARS-CoV-2 were designed to fail.

    -For the simple reason that the Pharmaceutical-Industrial Complex would thereby not miss out on Billions of Dollars, Euros, Pounds, Rupees & Yen in Profits gleaned from vaccinating 7 Billion people...

    | Login or Register (free) to reply publicly or privately   Email

  9. TopTop #36
    Jon Jackson's Avatar
    Jon Jackson

    Re: Dr. Campbell's COVID-19 Update

    Yes, this is wonderful news, and even I am convinced that hydroxychloroquine, rightly dosed (which means low-dose), may very well reduce mortality in COVID-19 patients.

    This is a very well-designed study, but perhaps the real clincher is the patient sample size: more that 8000 patients! This is data we can trust and believe. Then again, it is only ONE such study, and it is still the ONLY such study designed this well and with that kind of sample size. My lifelong policy about *anything* is that I want to see *three* studies that demonstrate the same thing.

    Nevertheless, this is a really good study, and I think it is likely the data will be reproduced by others.
    | Login or Register (free) to reply publicly or privately   Email

  10. Gratitude expressed by 2 members:

Similar Threads

  1. Pandemic Updates by Dr. Campbell
    By Valley Oak in forum Coronavirus
    Replies: 29
    Last Post: 07-27-2020, 12:06 PM
  2. Replies: 2
    Last Post: 05-26-2020, 08:54 PM
  3. Campbell Labels Will Disclose G.M.O. Ingredients
    By Barry in forum Health & Wellness
    Replies: 0
    Last Post: 01-11-2016, 02:57 PM
  4. Susan campbell, Please contact me
    By Everydaygoddess in forum General Community
    Replies: 0
    Last Post: 03-15-2008, 12:43 PM
  5. Wed. 5/9 - Dr. Susan Campbell at singles2couples
    By in forum Conscious Relationship
    Replies: 0
    Last Post: 05-07-2007, 12:31 PM

Tags (user supplied keywords) for this Thread